Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 5/20 | 0.66 |
| ▸ | GPR142 | Q7Z601 | 3/20 | 0.44 |
| ▸ | NAMPT | P43490 | 6/20 | 0.39 |
| ▸ | OGA | O60502 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | PKLR | P30613 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2988793 | 0.82 | RIPK1 (0.67) | RIPK1GPR142 | |
| SCHEMBL21800603 | 0.80 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL15055636 | 0.79 | RIPK1 (0.46) | RIPK1GPR142 | |
| SCHEMBL28369820 | 0.77 | AKR1C3 (0.52) | NAMPTAKR1C3AKR1C1 | |
| SCHEMBL29040775 | 0.77 | AKR1C3 (0.52) | NAMPTAKR1C3AKR1C1 | |
| SCHEMBL566589 | 0.76 | NAMPT (0.54) | NAMPTUSP30AKR1C3AKR1C1 | |
| SCHEMBL20297324 | 0.75 | RIPK1 (0.46) | RIPK1NAMPT | |
| SCHEMBL29501124 | 0.75 | RIPK1 (0.54) | RIPK1GPR142 | |
| SCHEMBL17957763 | 0.75 | RIPK1 (0.54) | RIPK1GPR142 | |
| SCHEMBL29040796 | 0.75 | AKR1C3 (0.50) | NAMPTUSP30AKR1C3AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11203600-B2 | Kinase inhibitors and uses thereof | DENALI THERAPEUTICS INC. (US) | 2021-12-21 | — | — | US | disclosed |
| EP-3624797-A1 | KINASE INHIBITORS AND USES THEREOF | Denali Therapeutics Inc. (US) | 2020-03-25 | — | — | EP | disclosed |
| US-20200087319-A1 | Kinase Inhibitors and Uses Thereof | DENALI THERAPEUTICS INC. (US) | 2020-03-19 | — | — | US | disclosed |
| WO-2018213632-A1 | KINASE INHIBITORS AND USES THEREOF | DENALI THERAPEUTICS INC. (US) | 2018-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087319-A1 | Kinase Inhibitors and Uses Thereof | MAP3K20, MAP3K6, MAP3K19 | RIPK1 353/4885GPR142 4436/4885NAMPT 909/4885 |
| US-11203600-B2 | Kinase inhibitors and uses thereof | MAP3K20, MAP3K6, MAP3K19 | RIPK1 353/4885GPR142 4436/4885NAMPT 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.